ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Indiana » Hematology Oncology

Top Hematology Oncology Prescribers in Indiana

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
ARTHUR ALUNDAY M.D.

Hematology Oncology

13,708

$736K

493
425 are 65+

7%
patients receiving schedule two controlled substances

Avg: 14%

11%
patients receiving schedule three controlled substances

Avg: 13%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

22%
prescriptions for brand name drugs

Avg: 16%

$54
Average prescription price

Avg: $334

ANNE GREIST M.D.

Hematology Oncology

3,400

$873K

245
108 are 65+

21%
patients receiving schedule two controlled substances

Avg: 14%

15%
patients receiving schedule three controlled substances

Avg: 13%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

34%
prescriptions for brand name drugs

Avg: 16%

$257
Average prescription price

Avg: $334

MARY MAYER M.D.

Hematology Oncology

3,302

$626K

493
396 are 65+

9%
patients receiving schedule two controlled substances

Avg: 14%

13%
patients receiving schedule three controlled substances

Avg: 13%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

13%
prescriptions for brand name drugs

Avg: 16%

$190
Average prescription price

Avg: $334

BILAL ANSARI M.D.

Hematology Oncology

2,891

$925K

480
391 are 65+

13%
patients receiving schedule two controlled substances

Avg: 14%

14%
patients receiving schedule three controlled substances

Avg: 13%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

19%
prescriptions for brand name drugs

Avg: 16%

$320
Average prescription price

Avg: $334

WILLIAM PLETCHER M.D.

Hematology Oncology

2,747

$408K

177
161 are 65+

0%
patients receiving schedule two controlled substances

Avg: 14%

14%
patients receiving schedule three controlled substances

Avg: 13%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

20%
prescriptions for brand name drugs

Avg: 16%

$149
Average prescription price

Avg: $334

SANG HUH MD

Hematology Oncology

2,278

$1.2M

338
268 are 65+

11%
patients receiving schedule two controlled substances

Avg: 14%

16%
patients receiving schedule three controlled substances

Avg: 13%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

15%
prescriptions for brand name drugs

Avg: 16%

$529
Average prescription price

Avg: $334

NAVEED CHOWHAN MD

Hematology Oncology

2,155

$734K

303
234 are 65+

9%
patients receiving schedule two controlled substances

Avg: 14%

8%
patients receiving schedule three controlled substances

Avg: 13%

6%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

17%
prescriptions for brand name drugs

Avg: 16%

$340
Average prescription price

Avg: $334

RAFAT ANSARI M.D.

Hematology Oncology

2,123

$847K

361
299 are 65+

13%
patients receiving schedule two controlled substances

Avg: 14%

12%
patients receiving schedule three controlled substances

Avg: 13%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

13%
prescriptions for brand name drugs

Avg: 16%

$399
Average prescription price

Avg: $334

JAMES JIN M.D.

Hematology Oncology

2,059

$295K

195
161 are 65+

23%
patients receiving schedule two controlled substances

Avg: 14%

13%
patients receiving schedule three controlled substances

Avg: 13%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

13%
prescriptions for brand name drugs

Avg: 16%

$143
Average prescription price

Avg: $334

RAYMOND HARWOOD MD

Hematology Oncology

1,955

$477K

325
282 are 65+

9%
patients receiving schedule two controlled substances

Avg: 14%

8%
patients receiving schedule three controlled substances

Avg: 13%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

12%
prescriptions for brand name drugs

Avg: 16%

$244
Average prescription price

Avg: $334

RUEMU BIRHIRAY MD

Hematology Oncology

1,950

$1.05M

268
219 are 65+

18%
patients receiving schedule two controlled substances

Avg: 14%

9%
patients receiving schedule three controlled substances

Avg: 13%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

16%
prescriptions for brand name drugs

Avg: 16%

$541
Average prescription price

Avg: $334

MICHAEL EPSTEIN MD

Hematology Oncology

1,887

$560K

340
291 are 65+

19%
patients receiving schedule two controlled substances

Avg: 14%

16%
patients receiving schedule three controlled substances

Avg: 13%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

16%
prescriptions for brand name drugs

Avg: 16%

$297
Average prescription price

Avg: $334

AHSANUL HAQUE M.D.

Hematology Oncology

1,861

$154K

228
183 are 65+

13%
patients receiving schedule two controlled substances

Avg: 14%

13%
patients receiving schedule three controlled substances

Avg: 13%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

18%
prescriptions for brand name drugs

Avg: 16%

$83
Average prescription price

Avg: $334

NIRAJ GUPTA MD

Hematology Oncology

1,808

$495K

259
214 are 65+

9%
patients receiving schedule two controlled substances

Avg: 14%

17%
patients receiving schedule three controlled substances

Avg: 13%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

13%
prescriptions for brand name drugs

Avg: 16%

$274
Average prescription price

Avg: $334

SURESH KUNAPAREDDY M.D.

Hematology Oncology

1,795

$423K

232
193 are 65+

13%
patients receiving schedule two controlled substances

Avg: 14%

22%
patients receiving schedule three controlled substances

Avg: 13%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

13%
prescriptions for brand name drugs

Avg: 16%

$236
Average prescription price

Avg: $334

BARBARA FULLER MD

Hematology Oncology

1,795

$374K

198
156 are 65+

14%
patients receiving schedule two controlled substances

Avg: 14%

21%
patients receiving schedule three controlled substances

Avg: 13%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

17%
prescriptions for brand name drugs

Avg: 16%

$208
Average prescription price

Avg: $334

WILLIAM KAMANDA M.D.

Hematology Oncology

1,739

$155K

118
77 are 65+

11%
patients receiving schedule two controlled substances

Avg: 14%

27%
patients receiving schedule three controlled substances

Avg: 13%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

18%
prescriptions for brand name drugs

Avg: 16%

$89
Average prescription price

Avg: $334

MARK BROWNING M.D.

Hematology Oncology

1,584

$394K

191
165 are 65+

13%
patients receiving schedule two controlled substances

Avg: 14%

16%
patients receiving schedule three controlled substances

Avg: 13%

6%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

16%
prescriptions for brand name drugs

Avg: 16%

$249
Average prescription price

Avg: $334

GHASSAN JANO M.D.

Hematology Oncology

1,580

$553K

223
181 are 65+

11%
patients receiving schedule two controlled substances

Avg: 14%

31%
patients receiving schedule three controlled substances

Avg: 13%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

13%
prescriptions for brand name drugs

Avg: 16%

$350
Average prescription price

Avg: $334

TAHIR NAQVI MD

Hematology Oncology

1,522

$538K

207
138 are 65+

16%
patients receiving schedule two controlled substances

Avg: 14%

20%
patients receiving schedule three controlled substances

Avg: 13%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

14%
prescriptions for brand name drugs

Avg: 16%

$354
Average prescription price

Avg: $334

MOHAMED FARHAT MD

Hematology Oncology

1,476

$274K

275
229 are 65+

11%
patients receiving schedule two controlled substances

Avg: 14%

18%
patients receiving schedule three controlled substances

Avg: 13%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

11%
prescriptions for brand name drugs

Avg: 16%

$186
Average prescription price

Avg: $334

MAQBOOL AHMED M.D.

Hematology Oncology

1,472

$586K

244
205 are 65+

10%
patients receiving schedule two controlled substances

Avg: 14%

18%
patients receiving schedule three controlled substances

Avg: 13%

6%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

14%
prescriptions for brand name drugs

Avg: 16%

$398
Average prescription price

Avg: $334

SHERYL ZIEGLER D.O.

Hematology Oncology

1,403

$691K

177
148 are 65+

12%
patients receiving schedule two controlled substances

Avg: 14%

19%
patients receiving schedule three controlled substances

Avg: 13%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

15%
prescriptions for brand name drugs

Avg: 16%

$493
Average prescription price

Avg: $334

PABLO BEDANO MD

Hematology Oncology

1,400

$726K

226
170 are 65+

23%
patients receiving schedule two controlled substances

Avg: 14%

17%
patients receiving schedule three controlled substances

Avg: 13%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

18%
prescriptions for brand name drugs

Avg: 16%

$518
Average prescription price

Avg: $334

FADI HAYEK MD

Hematology Oncology

1,377

$665K

181
136 are 65+

28%
patients receiving schedule two controlled substances

Avg: 14%

10%
patients receiving schedule three controlled substances

Avg: 13%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

17%
prescriptions for brand name drugs

Avg: 16%

$483
Average prescription price

Avg: $334

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank